He Changed the World of Organ Transplants. Would He Die Waiting for His Own?

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-23T16:16:49.583Z • Permanent link

David Bloom, a renowned New York transplant surgeon, spent decades navigating the complexities of the organ transplant system. His experience waiting for a heart transplant, however, laid bare the challenges he had been trying to fix. In 2016, Bloom's brother, Stephen, was in need of a heart transplant, but the waiting list was extensive, and the allocation process was opaque. Bloom's efforts to expedite the process were met with resistance from the transplant bureaucracy. The experience was a stark reminder of the systemic flaws that plague the organ transplant system.

Bloom's story is not an isolated incident. The organ transplant waiting list in the United States has grown to over 120,000 patients, with some waiting years for a transplant. The lack of transparency and fairness in the allocation process has sparked controversy and calls for reform. The issue is not limited to the United States; countries such as Canada and the United Kingdom also struggle with similar challenges. The World Health Organization (WHO) estimates that over 3,000 people die each year due to the shortage of available organs.

In 2019, the US Department of Health and Human Services (HHS) announced a new policy aimed at streamlining the transplant allocation process. The policy, known as the "Expanded Criteria Donor" (ECD) rule, allows hospitals to use a broader range of donors, including older and sicker individuals. While the policy has been praised for its potential to increase the number of available organs, its implementation has been met with resistance from some transplant centers. The controversy highlights the ongoing need for reform in the organ transplant system.

The challenges facing the organ transplant system have significant implications for companies, research communities, and markets. Companies such as United Therapeutics, a leading biotech firm, are developing innovative technologies aimed at increasing the supply of available organs. However, the lack of transparency in the allocation process makes it difficult for these companies to accurately predict demand and invest in new technologies. Research communities are also impacted, as the shortage of available organs hinders the development of new treatments and therapies.

The shortage of available organs also has significant economic implications. According to a study published in the Journal of the American Medical Association (JAMA), the cost of waiting for a transplant can exceed $1 million per year. This financial burden can have a disproportionate impact on vulnerable populations, including low-income individuals and those with limited access to healthcare. Policymakers are taking notice, with some calling for increased funding for organ transplantation research and development.

The challenges facing the organ transplant system are not unique to the United States. Similar issues exist in other developed countries, including Canada and the United Kingdom. In Canada, the organ transplant waiting list has grown to over 4,000 patients, with some waiting years for a transplant. The Canadian government has implemented various initiatives aimed at increasing the supply of available organs, including the development of new technologies and the creation of a national organ allocation system.